^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS G12C + PD-L1 expression

    i
    Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    Entrez ID:
    29126; 3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    2ms
    Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients. (PubMed, Thorac Cancer)
    PD-L1 expression was associated with well-defined clinicopathological and genomic features. These findings provide a comprehensive view of the expression of PD-L1 in patients with advanced NSCLC in a large Latin American cohort.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • PD-L1 overexpression • KRAS G12C • ALK positive • PD-L1 underexpression • PD-L1 negative • KRAS G12 • EGFR positive • KRAS G12C + PD-L1 expression • PD-L1-L
    3ms
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany. (PubMed, Eur J Cancer)
    First results from a real-world population confirm promising efficacy of sotorasib for the treatment of advanced KRAS p.G12C-mutated NSCLC. Patients with co-occurring KEAP1 mutations seem to derive less benefit.
    Journal • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12 • KRAS G12C + PD-L1 expression
    |
    Lumakras (sotorasib)
    3ms
    Extra-Hepatic Cholangiocarcinomas (ehCCA): a Genomic Landscape Comparison of Peri-Hilar (phCCA), Common Bile Duct (cbdCCA) and Gallbladder Cholangiocarcinomas (gbCCA) (USCAP 2024)
    ehCCA subtypes feature characteristic GA profiles that have potential to influence therapy selection with significantly lower frequencies of FGFR2 and IDH1 when compared with iCCA. In contrast, targetable GA in ERBB2 and KRAS G12C are more frequent in ehCCA than iCCA, and highest in gbCCA and cbdCCA respectively. GA in IO drug response associated biomarker frequencies (MSI, TMB level and PD-L1 expression) are similar in all 3 ehCCA subgroups.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    PD-L1 expression • KRAS G12C • HRD • KRAS G12 • KRAS G12C + PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    3ms
    Extra-Hepatic Cholangiocarcinomas (ehCCA): a Genomic Landscape Comparison of Peri-Hilar (phCCA), Common Bile Duct (cbdCCA) and Gallbladder Cholangiocarcinomas (gbCCA) (USCAP 2024)
    ehCCA subtypes feature characteristic GA profiles that have potential to influence therapy selection with significantly lower frequencies of FGFR2 and IDH1 when compared with iCCA. In contrast, targetable GA in ERBB2 and KRAS G12C are more frequent in ehCCA than iCCA, and highest in gbCCA and cbdCCA respectively. GA in IO drug response associated biomarker frequencies (MSI, TMB level and PD-L1 expression) are similar in all 3 ehCCA subgroups.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    PD-L1 expression • KRAS G12C • HRD • KRAS G12 • KRAS G12C + PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    5ms
    A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation (MTCS 2023)
    TBD
    P2 data • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS mutation + STK11 mutation • KRAS G12C + PD-L1 expression • PD-L1 expression + STK11 mutation
    |
    opnurasib (JDQ443)
    5ms
    Tumor immune microenvironment of KRAS G12C mutated pancreatic cancer as compared to other mutations and non-cancer pancreata. (ASCO-GI 2024)
    We identified increased infiltration of cytotoxic T lymphocytes and APCs in PDA patients with KRAS G12C mutations relative to other mutations and non-cancerous pancreata. Furthermore, while all PDAs had elevated PD-L1 expression on APCs, KRAS G12C tumors had minimal expression on epithelial cells suggesting a mutation specific impact and a potential role of immune checkpoint inhibitors in combination with G12C inhibitors.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12 • KRAS G12C + PD-L1 expression • KRAS expression
    5ms
    Peri-hilar cholangiocarcinoma (phCCA): A comparative comprehensive genomic profiling study. (ASCO-GI 2024)
    phCCA appears to be a distinctive form of ehCCA featuring significantly higher frequencies of potentially targetable ERBB2 and lower frequencies of targetable FGFR2 and IDH1 mutations, when compared to ihCCA. Predictive IO markers were similarly low in both ihCCA and ehCCA. >
    PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • KRAS G12C • BRAF mutation • PIK3CA mutation • IDH1 mutation • HRD • FGFR2 mutation • KRAS G12 • KRAS G12C + PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    6ms
    Landscape of KRAS G12C Mutations in Genitourinary Malignancies (SUO 2023)
    While KRAS G12C mutations are very rare in the major GU malignancies, a small proportion of such patients may benefit from emerging specific anti-KRAS G12C targeted therapies. Additionally, given the low prevalence of KRAS G12C mutations among major GU malignancies, investigation may be best approached in basket-type clinical trials using novel anti-KRAS G12C targeted therapies.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • TERT (Telomerase Reverse Transcriptase) • KDM6A (Lysine Demethylase 6A)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12 • TERT mutation • KRAS G12C + PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    6ms
    Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C. (PubMed, Front Oncol)
    Better overall survival and progression-free survival were observed in high PD-L1 expression tumors, regardless of KRAS mutation type. The heterogeneous nature of KRAS-mutant tumors and the presence of other co-mutations may contribute to different outcomes to immunotherapy-based strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • PD-L1 overexpression • KRAS G12C • KRAS G12 • KRAS G12C + PD-L1 expression • KRAS expression • PD-L1 mutation
    7ms
    A real-world retrospective study of immunotherapy in NSCLC patients with KRAS mutation (SITC 2023)
    Sotorasib and adagrasib are targeted drugs that have been proven effective and approved for KRAS G12C mutation, but they have not yet entered the Chinese market. Conclusions Bringing immunotherapy to first-line use in NSCLC patients with KRAS mutation might prolong their survival, and combination therapy is a preferable option compared to monotherapy. Positive PD-L1 expression and common KRAS mutations may serve as potential prognostic biomarkers for KRAS-mutated NSCLC patients who receive immunotherapy.
    Retrospective data • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • STK11 mutation • KRAS G12 • KRAS G12C + PD-L1 expression • KRAS expression • PD-L1 mutation
    |
    Lumakras (sotorasib) • Krazati (adagrasib)
    7ms
    Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment in pre-clinical humanized NSCLC mouse models (SITC 2023)
    Notably, AMG510 provided complementary immune modulatory benefits that support the mechanism of Nivolumab. The findings suggest that combining KRAS G12C inhibitor with anti-PD-1 antibody holds a promising therapeutic potential for NSCLC patients.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • CD34 (CD34 molecule)
    |
    KRAS mutation • PD-L1 overexpression • KRAS G12C • KRAS G12C + PD-L1 expression • KRAS expression
    |
    Opdivo (nivolumab) • Lumakras (sotorasib)